| DB ID | MyCo_5037 |
| Title | Application of Mass Spectrometry Technology to Early Diagnosis of Invasive Fungal Infections |
| Year | 2016 |
| PMID | 27605710 |
| Fungal Diseases involved | Invasive aspergillosis |
| Associated Medical Condition | None |
| Genus | Aspergillus |
| Species | fumigatus |
| Organism | Aspergillus fumigatus |
| Ethical Statement | All sera used in this study were obtained from patients monitored at Lille University Hospital. When no results were available from routine tests, BDG and mannan levels were determined retrospectively from residual frozen samples. No additional sampling was necessary. As sera were taken from a registered biological collection, patient consent was not required according to French law. Agreement for the establishment of a biological collection of IFI samples was obtained from the French Ministry of Education and Research under reference DC-2008-642. Institutional review board approval was given by the Comité de Protection des Personnes Nord-Ouest IV, the ethical committee of the institution. |
| Site of Infection | None |
| Opportunistic invasive | Invasive |
| Sample type | Body fluid |
| Sample source | Serum |
| Host Group | Human |
| Host Common name | Human |
| Host Scientific name | Homo sapiens |
| Biomarker Name | MS-DS |
| Biomarker Full Name | Serum disaccharide |
| Biomarker Type | Prognostic |
| Biomolecule | Protein |
| Geographical Location | France |
| Cohort | This retrospective study included 48 patients (23 IC patients [74 serum samples], 15 IA patients [40 serum samples], and 10 MM patients [15 serum samples]) and 49 appropriate controls (102 serum samples). Patients were selected from the database of Lille University Hospital according to the following criteria: (i) classification as having proven or probable IFI according to European Organization for the Research and Treatment of Cancer/Mycoses Study Group (EORTC/MSG) criteria and (ii) availability of sera drawn around the time when clinical/mycological/imaging evidence of IFI was obtained. (ii) Control subjects consisted of hospitalized patients in ICUs and hematology wards who were considered appropriate controls with major risk factors for IFIs. In the ICU, we selected 29 control patients for IC who had previously been enrolled in a prospective study and for whom 82 serum samples were drawn sequentially in parallel with the determination of the colonization index. In oncohematology wards, controls for IA consisted of 20 patients for whom regular monitoring of GM was performed (1 serum sample per patient). Both groups corresponded to suitable controls for MM. |
| Cohort No. | 48 Patients and 49 Control |
| Age Group | None |
| P Value | None |
| Sensitivity | 0.83 |
| Specificity | 0.81 |
| Positive Predictive Value | None |
| MIC | None |
| Fold Change | None |
| Pathway | None |
| Disease Introduction Mechanism | Invasive candidiasis (IC) and invasive aspergillosis (IA) are major life-threatening nosocomial invasive fungal infections (IFIs). Although less prevalent, mucormycosis (MM) is an emerging problem. Progress in antifungal therapy has not significantly reduced the high rates of morbidity and mortality associated with IFIs, particularly in intensive care units (ICUs) and oncohematology units, due to difficulties in obtaining an early diagnosis, an important condition for a favorable outcome. Difficulties in the biological detection of IFIs are related to the low yield of culture-based methods; blood cultures are positive in only 50% of episodes of IC and in anecdotic cases of IA. |
| Technique | Analytic |
| Analysis Method | MALDI-TOF MS |
| ELISA kits | ELISA- Platelia Aspergillus Ag kit (Bio-Rad) |
| Assay Data | FDA- Fungitell® beta-D-glucan (BDG) assay |
| Validation Techniques used | MALDI-TOF MS |
| Up Regulation Down Regulation | Positive |
| Sequence Data | None |
| External Link | None |
